Cigalah Medpharm Announces the Launch in Saudi Arabia and United Arab Emirates of Nexodyn® AOS, the Tehclo-Based Wound Cleanser Developed by the Swiss Pharma Company APR
Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based cleanser for acute and chronic wound management, is now starting to be available in Saudi Arabia and United Arab Emirates (UAE), promoted and commercialized by the leading pharmaceutical company Cigalah Medpharm, part of Cigalah Group, following an exclusive partnership with the Swiss Pharma company APR Applied Pharma Research (“APR”).
The current size of wound care market in Saudi Arabia and United Arab Emirates accounts for almost 70 million USD and it’s expected to keep growing in the next years because of the aging of the population and the increasing prevalence of chronic wounds, which represent roughly the 70% of the total market. As confirmed by market research, strong is the need from Healthcare Professionals (HCP) of new treatment options to ensure a faster and effective wound healing.
The innovative wound cleanser, Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, offers to HCPs and caregivers a new treatment option to effectively address the wound healing complexity. Thanks to its distinctive physico-chemical properties, Nexodyn® AOS promotes wound healing restart by creating the ideal microenvironment to sustain the physiological healing process and favoring an optimized lesion closure. As it contains hypochlorous acid, it can prevent contamination or contribute to counteract local infections by exerting a local antimicrobial effect on the wound surface.
“We are very proud about our collaboration with APR and that Cigalah Medpharm’s product portfolio got enriched with such an outstanding product as Nexodyn® AOS. The launch of Nexodyn® is the beginning of a long-term success story and we are very confident that with professionalism, experience and our market approach we will achieve our targets together – to revolutionize the wound care market in the MENA region.” said Dr. Ahdy Elsays, Managing Director of Cigalah Medpharm.
Cigalah Medpharm will support the distribution and the promotion of Nexodyn® AOS with a comprehensive range of activities addressing the HCPs at different levels, from KOLs to hospitals, such as congresses, as well as training courses and digital campaigns, with the purpose of establishing Nexodyn® AOS as the first wound cleanser restarting the physiological healing process of wounds.
”We are very proud to make Nexodyn® AOS finally available to HCPs and patients on Saudi Arabia and UAE markets. We believe that Nexodyn® AOS, thanks to its unique features supported by our patented technology Tehclo®, is the right answer to the increasing demand of advanced and consistent solutions in the wound care, as while it cleanses the wound it creates the conditions for healing restart.” said Paolo Galfetti, Chief Executive Officer of APR.
The launch of Nexodyn® AOS in Saudi Arabia and United Arab Emirates comes after previous marketing of the product in Italy and US, and other markets will follow in the next year as a result of the company partnerships which span from Europe to Africa and Asia, confirming Nexodyn® AOS appeal and efficacy among the available wound care solutions.
About Nexodyn® AcidOxidizing Solution (AOS)
Nexodyn® AcidOxidizing Solution (AOS) is a sprayable Active Cleanser with an ancillary antimicrobial activity developed for acute and chronic wound management.
A wide array of clinical experiences and studies suggest Nexodyn® AcidOxidizing Solution (AOS) to perform as a Wound healing Restarter by creating the ideal microenvironment to sustain the physiological healing process. Restarting wound healing, favoring an optimized lesion closure and ensuring a favorable safety and tolerability profile, is especially relevant with chronic wounds.
Developed based on APR’s proprietary and patented technology Tehclo®, the product is a newly conceived solution with three main features: highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential (ORP >1.000 mV).
Nexodyn® AcidOxidizing Solution (AOS) is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, and vascular ulcers), post-surgical wounds, burns and other lesions.
As observed in non-clinical experiments and clinical experiences, Nexodyn® AcidOxidizing Solution (AOS) has synergic physico-chemical properties sustaining the restart of wound healing to the benefit of patients and HCPs who can be confident of the reactivation of the physiological healing process concomitantly to protection and management of uncontrolled microbial growth. Nexodyn® AcidOxidizing Solution (AOS) shows favorable safety and tolerability profile and the clinical experiences performed confirm its high relief sensation and comfort at application as well as wound-associated pain reduction.
For more info, please visit: http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and commercializes, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. The company has started up a direct sale and marketing organizations in selected countries in rare disease products area.
About Cigalah Medpharm
Cigalah Group is a key player in the Middle East and North Africa healthcare market with a total turnover exceeding 1 billion dollars. Cigalah Group is covering many therapeutic areas through collaborations and partnerships with key pharma multinational corporations including Bayer, BI, Takeda, Amgen and Gilead. Cigalah is significantly expanding its presence in the MENA region thanks to Cigalah Medpharm and Cigalah Pharmaceuticals, the UAE based subsidiaries of Cigalah Group. Cigalah Medpharm is the gateway to the Middle East representing global brands in parapharmaceuticals, cosmeceutical and healthcare products who wish to establish a strong base in the region. The paradigm of the organizations success is built on happy and satisfied customers and the choice of working only with partners and producers, who share the same ethics and high quality standards.
APR Applied Pharma Research s.a.:
Paolo Galfetti, T +41 91 6957020
Chief Executive Officer
e-mail to: email@example.com
Dr. Ahdy Elsays, T +971 4 4215334
Cigalah Medpharm Trading LLC
e-mail to : firstname.lastname@example.org
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Bartek Ingredients Expands Leadership Team22.3.2019 01:35:00 EET | Tiedote
Bartek Ingredients Inc. recently completed a 4,000 ton/year capacity expansion for its malic and food-grade fumaric acid production facility, and today it announces the expansion of its leadership team, with the hiring of Jeff Billig as Vice President of Marketing & Business Development and Heinrich G. Schaefer as International Sales Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005785/en/ The global leader in malic and fumaric acid ingredients expands its leadership team. (Photo: Business Wire) Bartek’s investment in both its team and facilities reinforces its position as the leader in malic and fumaric acid globally and aligns with its mission to facilitate growth and increase global reach to better serve existing customers and markets while opening up new ones. Bartek’s addition of Billig and Schaefer lays the foundation for additional resource investment in the near future while rapidly increasing its sa
Hansard Global Plc Selects SaaS-Based Majesco LifePlus Solutions to Transform Their Business21.3.2019 23:30:00 EET | Tiedote
Majesco (NASDAQ:MJCO), a global leader of cloud core insurance software, today announced that Hansard Global plc, a FTSE listed business, selected Majesco Life IllustratePlus, Majesco Life AdminPlus, and Majesco Life DistributionPlus to support its ambitious growth plans. Hansard Global plc, which is headquartered on the Isle of Man, provides innovative financial products and services for financial advisors and their international clients, leveraging the latest technology to deliver an award-winning online proposition and best-in-class service. This is the third UK win announced in the last 12 months, following the launch of the SaaS offering in February of 2016 and has received a hugely positive response from the industry, endorsed by numerous industry awards. Majesco has established itself as a market leader in cloud-based core insurance solutions within the individual life and pensions sector. Ollie Byrne, Chief Strategy Officer at Hansard Global plc, commented “Our current system h
ResMed to Host an Investor Meeting on April 4, 201921.3.2019 23:05:00 EET | Tiedote
ResMed (NYSE: RMD) (ASX: RMD) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software. Additional information regarding the investor meeting, including the specific time and webcast link for the presentations, will be made available approximately one week prior to the event and may be accessed by visiting http://investor.resmed.com. Space for the event is limited and therefore in-person attendance is available by invitation only. Presentations at the investor meeting will be transmitted by a live webcast, which may be accessed by visiting http://investor.resmed.com. A replay of the webcast will be accessible on our website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible for approximately one year thereafter. Abo
KILL OnMiners Mining Rigs Offering the Biggest Hash-Rate in the Market21.3.2019 22:53:00 EET | Tiedote
Business Wire requests that NewsItemId: 20190320005122, OnMiners press release "OnMiners Mining Rigs Offering the Biggest Hash-Rate in the Market" issued March 20, 2019 be removed. View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005122/en/ Contact information Business Wire, France +33 (0) 1 56 88 29 40
KILL OnMiners Changing the Game in Cryptocurrency Mining21.3.2019 22:51:00 EET | Tiedote
Business Wire requests that NewsItemId: 20190318005779, OnMiners press release "OnMiners Changing the Game in Cryptocurrency Mining" issued March 18, 2019 be removed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005779/en/ View source version on businesswire.com: https://www.businesswire.com/news/home/20190318005779/en/ Contact information Business Wire, France +33 (0) 1 56 88 29 40
Her Excellency Sheikha Hind Attends International Universities Arabic Debating Championship Closing Ceremony21.3.2019 18:03:00 EET | Tiedote
Her Excellency Sheikha Hind bint Hamad Al Thani, Vice Chairperson and CEO of Qatar Foundation (QF), attended the closing ceremony of the fifth edition of the International Universities Arabic Debating Championship (IUDC) organized by QatarDebate, a member of QF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005482/en/ Princess Sumaya University for Technology in Jordan takes First Place (Photo: AETOSWire) The championship – held under the patronage of Her Excellency Sheikha Hind bint Hamad Al Thani – took place at Qatar National Convention Centre from March 16-20, 2019, and included 107 teams from 51 Arab and non-Arab countries. During the ceremony, Her Excellency Sheikha Hind presented the winners with their awards. The debate team from Princess Sumaya University for Technology in Jordan took first place in this year’s edition of IUDC. The boys’ team from Qatar University was awarded second place, while the team from
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme